480-16-0

Usage

Uses

Used in Pharmaceutical Applications:
Morin is used as a P450 and ATPase inhibitor, which contributes to its potential applications in the pharmaceutical industry. It has been shown to inhibit PIM-1 kinase in vitro (IC50 = 2.7 μM) and reduce the activity of cytochrome P450 isoform 3A4 in liver microsomes. These properties make Morin a promising candidate for the development of new drugs targeting various diseases.
Used in Antioxidant and Anti-Inflammatory Applications:
Morin is used as an antioxidant and anti-inflammatory agent due to its ability to reduce CD36 expression and oxLDL uptake in U937-derived macrophages. This action helps in mitigating oxidative stress and inflammation, which are common factors in many diseases.
Used in Neuroinflammation Suppression:
Morin is used as a potential suppressor of lipopolysaccharide-induced neuroinflammation. Its radical scavenging ability makes it a valuable compound for the development of treatments targeting neuroinflammatory conditions.

Safety Profile

Moderately toxic by intraperitoneal route. Mutation data reported. When heated to decomposition it emits acrid smoke and irritating fumes.

Purification Methods

Stir morin at room temperature with ten times its weight of absolute EtOH, then leave overnight to settle. Filter it off, and evaporate under a heat lamp to one-tenth its volume. An equal volume of water is added, and the precipitated morin is filtered off, dissolved in the minimum amount of EtOH and again precipitated with an equal volume of water. The precipitate is filtered off, washed with water and dried at 110o for 1hour (yield ca 2.5%.). [Perkins & Kalkwarf Anal Chem 28 1989 1956.] It complexes with W and Zr. [Beilstein 18 H 239, 18 III/IV 3468, 18/5 V 492.]

InChI:InChI=1/C15H10O7/c16-6-1-2-8(9(18)3-6)15-14(21)13(20)12-10(19)4-7(17)5-11(12)22-15/h1-5,16-19,21H

Upstream product

• 1173997-99-3 morin 3-O-α-L-rhamnopyranoside 
• 480-66-0 2,4,6-trihydroxyacetophenone 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 84757-50-6 2-(2,4-dimethoxyphenyl)-3-hydroxy-5,7-dimethoxy-4H-chromen-4-one 
• 249278-28-2 2,4,6-trihydroxyacetophenone monohydrate 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 

Downstream Products

• 7555-80-8 pentamethyl morin 
• 79400-75-2 morin-5'-sulfonic acid 
• 89-86-1 4-hydroxysalicylic acid 
• 144-62-7 oxalic acid 
• 108-73-6 3,5-dihydroxyphenol 
• 108-46-3 recorcinol 
• 1707-75-1 2,2-diphenyl-1-picrylhydrazine 
• 939125-94-7 Eu(III)(morin^(1-))3 
• 502590-85-4 C₁₅H₁₀O₇*C₄₂H₇₀O₃₅ 
• 79400-76-3 morin-5'-sulfonic acid, sodium salt 

Relevant academic research and scientific papers

SYNTHESIS OF MORIN AND MORIN DERIVATIVES

The invention relates to a method for directly producing morin derivatives and high-purity morin of formula (I). The invention also relates to morin derivatives and high-purity morin that can be obtained using the claimed method.

The total synthesis of (±)-sanggenol F

A concise and efficient total synthesis of sanggenol F (1) in racemic form has been completed via a sequence of 15 steps with an overall yield of 3.1%, starting from commercially available 2,4,6-trihydroxyacetophenone. Meanwhile, a semisynthesis of sanggenol F racemate has also been achieved in 11.1% overall yield via 7 steps with naturally-occurring morin (2) as the starting material. One step and a stepwise approach were employed to construct the two prenyl side chains at 2- and 6-positions by Claisen rearrangement reaction.

Pharmacophore and docking-based hierarchical virtual screening for the designing of aldose reductase inhibitors: Synthesis and biological evaluation

A set of 54 studied flavonoid inhibitors of aldose reductase (ALR2) enzyme has been utilized for pharmacophore modeling and 3D-QSAR analysis using "PHASE" program of Schr?dinger software. The generated pharmacophore model (AADRR.1109) was challenged to screen "PHASE" database to identify new ALR2 inhibitors. The retrieved hits were employed for docking analysis and pharmacokinetic parameter calculation to obtain orally active molecules. To predict the activity of final retrieved hits, 3D-QSAR model was developed, and the best model was selected on the basis of various statistical parameters (Rtrain 2 0.719; Q test 2 0.647 and SD 0.663). Totally five screened molecules which showed better enhanced predicted activity were synthesized and evaluated for in vitro ALR2 inhibitory activity. All tested molecules showed ALR2 inhibitory activity (IC50) below 40 μM. Additionally, the free radical scavenging potential of synthesized molecules was also determined which played a useful role to control the progression of diabetic complications. All molecules showed good antioxidant potential, thus the designed molecules, in future, could be explored to ameliorate the development of diabetic complications.

Flavonol glycosides from muehlenbeckia platyclada and their anti-inflammatory activity

A new flavonol, morin-3-O-α-rhamnopyranoside (1), along with four known flavonols, kaempferol 3-O-α-rhamnopyranoside (2), kaempferol 3-O-β-glucopyranoside (3), quercetin 3-O-α-rhamnopyranoside (4) and (+)-catechin (5), were isolated from the methanolic ex

Method for suppressing sorbate- and/or sorbic acid-induced discoloration

Compositions which comprise sorbic acid and/or one or more sorbates, and a flavonoid and/or flavonoid derivative, a method for the preparation thereof, and their use.